A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-Hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection
This study enrolls adults and children who have received a positive COVID-19 test result and were tested in the last 72 hours. The purpose of this study is to learn if an inhaler treatment gives better outcomes for people with COVID-19.
You will use the study medication inhaler or a placebo twice a day for a month and track your symptoms in an online journal twice a day. During the study a member of our research team will come to your home two times to meet with you, and you will answer some questions by phone throughout the study. You will not need to visit our office. All parts of the study will be done via phone, online, or in your home (using protective gear and social distancing measures).
The primary study objective is to assess whether treatment with ciclesonide metered-dose inhaler (MDI) plus standard supportive care reduces the incidence of hospital admissions or death compared with placebo plus standard supportive care in non-hospitalized patients with symptomatic Coronavirus Disease 2019 (COVID-19) infection.
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
-Adults and children ages 12+
-Have had a positive COVID-19 test result and were tested in the last 72 hours (3 days).
-Have cough, fever, or shortness of breath.
-Are not in need of hospitalization.
Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email firstname.lastname@example.org and someone will assist you.